Immatics N.V. Ordinary Shares (IMTX) Stock
Key stats
- Market cap
- $1.02B
- Price / Earnings ratio
- -3.7x
- EPS (TTM)
- -$1.83
- Volume
- Loading
- 52-week high
- $12.41
- 52-week low
- $6.09
Source: third-party data provider, as of November 13, 2026
Compare with IMTX
Recent news

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
IMTX

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
IMTX

New Strong Buy Stocks for February 12th
New Strong Buy Stocks for February 12th
IMTX

New Strong Buy Stocks for January 9th
New Strong Buy Stocks for January 9th
IMTX
Technical indicators
- RSI 14
- 40.51
- MACD 12/26/9
- -0.36
- EMA 9 of MACD
- -0.35
- MACD histogram
- -0.02
- SMA 50
- $7.83
- Price below SMA 50
- EMA 50
- $7.66
- Price below EMA 50
- SMA 200
- $9.46
- Price below SMA 200
- EMA 200
- $9.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
IMTX

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
IMTX

New Strong Buy Stocks for February 12th
New Strong Buy Stocks for February 12th
IMTX

New Strong Buy Stocks for January 9th
New Strong Buy Stocks for January 9th
IMTX

Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine development
Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine development
IMTX

Immatics shares rise on Moderna cancer collaboration
Immatics shares rise on Moderna cancer collaboration
IMTX

Moderna, Immatics to work jointly on cancer vaccines
Moderna, Immatics to work jointly on cancer vaccines
IMTX

Immatics shares jump after investment from Bristol Myers Squibb
Immatics shares jump after investment from Bristol Myers Squibb
IMTX

BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
IMTX

Bristol Myers Squibb, Immatics expand CAR-T agreement
Bristol Myers Squibb, Immatics expand CAR-T agreement
IMTX
About Immatics N.V. Ordinary Shares
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Harpreet Singh Ph.D. | CEO, MD, Member of Management Board & Executive Director | 1975 |
| Dr. Venkat Ramanan Ph.D. | Chief Financial Officer | 1970 |
| Ms. Amie Krause | Chief People Officer | 1973 |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder & Member of the Scientific Advisory Board | — |
| Dr. Toni Weinschenk Ph.D. | Co-Founder & Chief Innovation Officer | 1970 |
| Mr. Steffen Walter Ph.D. | Chief Operations Officer | 1977 |
| Mr. Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting & Accounting | — |
| Mr. James Pepin J.D. | General Counsel & Corporate Secretary | — |
| Ms. Lauren Schroeder | Vice President of Marketing | — |
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Development Officer | 1967 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 40.51
- MACD 12/26/9
- -0.36
- EMA 9 of MACD
- -0.35
- MACD histogram
- -0.02
- SMA 50
- $7.83
- Price below SMA 50
- EMA 50
- $7.66
- Price below EMA 50
- SMA 200
- $9.46
- Price below SMA 200
- EMA 200
- $9.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $15.00
- Average
- $15.00
- High
- $15.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.2 | +9.8 | +6.7 | -9.1 | -12.1 | +5.7 | -6.9 | -14.7 | -5.2 |



